Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Saikosaponin A
2. Saikosaponin B
3. Saikosaponin B1
4. Saikosaponin B2
5. Saikosaponin B3
6. Saikosaponin B4
7. Saikosaponin C
8. Saikosaponin K
9. Saikosaponin L
10. Saikosaponins
1. 20874-52-6
2. Beta-d-galactopyranoside, (3beta,4alpha,16alpha)-13,28-epoxy-16,23-dihydroxyolean-11-en-3-yl 6-deoxy-3-o-beta-d-glucopyranosyl-
3. Ur635j3f00
4. (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-3,5-dihydroxy-2-[[(1s,2r,4s,5r,8r,9r,10s,13s,14r,17s,18r)-2-hydroxy-9-(hydroxymethyl)-4,5,9,13,20,20-hexamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracos-15-en-10-yl]oxy]-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
5. Saikosaponins
6. Saikosaponin D From Bupleurum Falcatnum
7. Schembl929710
8. Unii-ur635j3f00
9. Chembl3613719
10. Dtxsid301317467
11. (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-3,5-dihydroxy-2-[hydroxy-(hydroxymethyl)-hexamethyl-[?]yl]oxy-6-methyl-tetrahydropyran-4-yl]oxy-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol
12. Hy-n0250
13. Mfcd09028095
14. S5454
15. Akos016034270
16. Zinc247647500
17. Ccg-270465
18. Cs-0008281
19. N1887
20. Q-100262
21. Q27291219
22. .beta.-d-galactopyranoside, (3.beta.,4.alpha.,16.alpha.)-13,28-epoxy-16,23-dihydroxyolean-11-en-3-yl 6-deoxy-3-o-.beta.-d-glucopyranosyl-
23. Beta-d-galactopyranoside, (3beta,4alpha,16alpha)-13,28-epoxy-16,23-dihydroxyolean-11-en-3-yl 6-deoxy-3-o-beta-d-glucopyranosyl
| Molecular Weight | 781.0 g/mol |
|---|---|
| Molecular Formula | C42H68O13 |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 6 |
| Exact Mass | 780.46599222 g/mol |
| Monoisotopic Mass | 780.46599222 g/mol |
| Topological Polar Surface Area | 208 Ų |
| Heavy Atom Count | 55 |
| Formal Charge | 0 |
| Complexity | 1490 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 21 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
Antineoplastic Agents, Phytogenic
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
11
PharmaCompass offers a list of Saikosaponin D API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Saikosaponin D manufacturer or Saikosaponin D supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Saikosaponin D manufacturer or Saikosaponin D supplier.
PharmaCompass also assists you with knowing the Saikosaponin D API Price utilized in the formulation of products. Saikosaponin D API Price is not always fixed or binding as the Saikosaponin D Price is obtained through a variety of data sources. The Saikosaponin D Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Saikosaponin D manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Saikosaponin D, including repackagers and relabelers. The FDA regulates Saikosaponin D manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Saikosaponin D API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Saikosaponin D supplier is an individual or a company that provides Saikosaponin D active pharmaceutical ingredient (API) or Saikosaponin D finished formulations upon request. The Saikosaponin D suppliers may include Saikosaponin D API manufacturers, exporters, distributors and traders.
Saikosaponin D Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Saikosaponin D GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Saikosaponin D GMP manufacturer or Saikosaponin D GMP API supplier for your needs.
A Saikosaponin D CoA (Certificate of Analysis) is a formal document that attests to Saikosaponin D's compliance with Saikosaponin D specifications and serves as a tool for batch-level quality control.
Saikosaponin D CoA mostly includes findings from lab analyses of a specific batch. For each Saikosaponin D CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Saikosaponin D may be tested according to a variety of international standards, such as European Pharmacopoeia (Saikosaponin D EP), Saikosaponin D JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Saikosaponin D USP).
